Skip to main content
Erschienen in: Diabetologia 6/2004

01.06.2004 | Article

Interleukin-6 and tumor necrosis factor-α are not increased in patients with Type 2 diabetes: evidence that plasma interleukin-6 is related to fat mass and not insulin responsiveness

verfasst von: A. L. Carey, C. R. Bruce, M. Sacchetti, M. J. Anderson, D. B. Olsen, B. Saltin, J. A. Hawley, M. A. Febbraio

Erschienen in: Diabetologia | Ausgabe 6/2004

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

Our aim was to examine the possible direct relationship of interleukin-6 and TNFα with insulin sensitivity in humans.

Methods

We carried out two series of euglycaemic-hyperinsulinaemic clamp experiments. In the first (CLAMP1), skeletal muscle mRNA expression and plasma concentrations of IL-6 and TNFα were examined in patients with Type 2 diabetes (n=6), subjects matched for age (n=6), and young healthy (n=11) control subjects during a 120-min supra-physiological hyperinsulinaemic (40 mU·m−2·min−1) euglycaemic clamp. In the second series of experiments (CLAMP2), patients with Type 2 diabetes (n=6) and subjects matched for age (n=7) were studied during a 240-min high-physiological hyperinsulinaemic (7 mU·m−2·min−1) euglycaemic clamp, during which arterial and venous (femoral and subclavian) blood samples were measured for IL-6 and TNFα flux.

Results

In both experiments the glucose infusion rate in the patients was markedly lower than that in the other groups. In CLAMP1, basal skeletal muscle IL-6 and TNFα mRNA were the same in all groups. They were not affected by insulin and they were not related to the glucose infusion rate. In CLAMP2, neither cytokine was released from the arm or leg during insulin stimulation in either group. In both experiments plasma concentrations of these cytokines were similar in the patients and in the control subjects, although in CLAMP1 the young healthy control group had lower (p<0.05) plasma IL-6 concentrations. Using data from all subjects, a strong positive correlation (r=0.85; p<0.00001) was observed between basal plasma IL-6 and BMI. Conversely, a negative relationship (r=−0.345; p<0.05) was found between basal plasma TNFα and BMI, although this was not significant when corrected for BMI. When corrected for BMI, no relationship was observed between either basal plasma IL-6 or TNFα and GIR.

Conclusions/interpretation

These data show that the increased circulating IL-6 concentrations seen in patients with Type 2 diabetes are strongly related to fat mass and not insulin responsiveness, and suggest that neither IL-6 nor TNFα are indicative of insulin resistance.
Literatur
1.
Zurück zum Zitat Bastard JP, Jardel C, Bruckert E et al. (2000) Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab 85:3338–3342 Bastard JP, Jardel C, Bruckert E et al. (2000) Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab 85:3338–3342
2.
Zurück zum Zitat Bastard JP, Maachi M, Van Nhieu JT et al. (2002) Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab 87:2084–2089CrossRefPubMed Bastard JP, Maachi M, Van Nhieu JT et al. (2002) Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab 87:2084–2089CrossRefPubMed
3.
Zurück zum Zitat Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G (2001) Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 280:E745–E751PubMed Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G (2001) Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 280:E745–E751PubMed
4.
Zurück zum Zitat Saghizadeh M, Ong JM, Garvey WT, Henry RR, Kern PA (1996) The expression of TNF alpha by human muscle. Relationship to insulin resistance. J Clin Invest 97:1111–1116PubMed Saghizadeh M, Ong JM, Garvey WT, Henry RR, Kern PA (1996) The expression of TNF alpha by human muscle. Relationship to insulin resistance. J Clin Invest 97:1111–1116PubMed
5.
Zurück zum Zitat Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS (1997) Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 389:610–614PubMed Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS (1997) Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 389:610–614PubMed
6.
Zurück zum Zitat Fernandez-Real JM, Broch M, Vendrell J et al. (2000) Interleukin-6 gene polymorphism and insulin sensitivity. Diabetes 49:517–520 Fernandez-Real JM, Broch M, Vendrell J et al. (2000) Interleukin-6 gene polymorphism and insulin sensitivity. Diabetes 49:517–520
7.
Zurück zum Zitat Pickup JC, Mattock MB, Chusney GD, Burt D (1997) NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 40:1286–1292CrossRefPubMed Pickup JC, Mattock MB, Chusney GD, Burt D (1997) NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 40:1286–1292CrossRefPubMed
8.
Zurück zum Zitat Lyngso D, Simonsen L, Bulow J (2002) Interleukin-6 production in human subcutaneous abdominal adipose tissue: the effect of exercise. J Physiol 543:373–378CrossRefPubMed Lyngso D, Simonsen L, Bulow J (2002) Interleukin-6 production in human subcutaneous abdominal adipose tissue: the effect of exercise. J Physiol 543:373–378CrossRefPubMed
9.
Zurück zum Zitat Steensberg A, Fischer CP, Sacchetti M et al. (2003) Acute interleukin-6 administration does not impair muscle glucose uptake or whole-body glucose disposal in healthy humans. J Physiol 548:631–638CrossRefPubMed Steensberg A, Fischer CP, Sacchetti M et al. (2003) Acute interleukin-6 administration does not impair muscle glucose uptake or whole-body glucose disposal in healthy humans. J Physiol 548:631–638CrossRefPubMed
10.
Zurück zum Zitat Wallenius V, Wallenius K, Ahren B et al. (2002) Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 8:75–79CrossRefPubMed Wallenius V, Wallenius K, Ahren B et al. (2002) Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 8:75–79CrossRefPubMed
11.
Zurück zum Zitat Mohamed-Ali V, Goodrick S, Rawesh A et al. (1997) Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 82:4196–4200PubMed Mohamed-Ali V, Goodrick S, Rawesh A et al. (1997) Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 82:4196–4200PubMed
12.
Zurück zum Zitat Febbraio MA, Pedersen BK (2002) Muscle-derived interleukin-6: mechanisms for activation and possible biological roles. FASEB J 16:1335–1347CrossRefPubMed Febbraio MA, Pedersen BK (2002) Muscle-derived interleukin-6: mechanisms for activation and possible biological roles. FASEB J 16:1335–1347CrossRefPubMed
13.
Zurück zum Zitat Keller C, Steensberg A, Pilegaard H et al. (2001) Transcriptional activation of the IL-6 gene in human contracting skeletal muscle: influence of muscle glycogen content. FASEB J 15:2748–2750PubMed Keller C, Steensberg A, Pilegaard H et al. (2001) Transcriptional activation of the IL-6 gene in human contracting skeletal muscle: influence of muscle glycogen content. FASEB J 15:2748–2750PubMed
14.
Zurück zum Zitat Steensberg A, van Hall G, Osada T, Sacchetti M, Saltin B, Pedersen BK (2000) Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6. J Physiol 529:237–242PubMed Steensberg A, van Hall G, Osada T, Sacchetti M, Saltin B, Pedersen BK (2000) Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6. J Physiol 529:237–242PubMed
15.
Zurück zum Zitat Carey AL, Lamont B, Andrikopoulos S, Koukoulas I, Proietto J, Febbraio MA (2003) Interleukin-6 gene expression is increased in insulin-resistant rat skeletal muscle following insulin stimulation. Biochem Biophys Res Commun 302:837–840CrossRefPubMed Carey AL, Lamont B, Andrikopoulos S, Koukoulas I, Proietto J, Febbraio MA (2003) Interleukin-6 gene expression is increased in insulin-resistant rat skeletal muscle following insulin stimulation. Biochem Biophys Res Commun 302:837–840CrossRefPubMed
16.
Zurück zum Zitat Steensberg A, Febbraio MA, Osada T et al. (2001) Interleukin-6 production in contracting human skeletal muscle is influenced by pre-exercise muscle glycogen content. J Physiol 537:633–639PubMed Steensberg A, Febbraio MA, Osada T et al. (2001) Interleukin-6 production in contracting human skeletal muscle is influenced by pre-exercise muscle glycogen content. J Physiol 537:633–639PubMed
17.
Zurück zum Zitat Winkler G, Lakatos P, Salamon F et al. (1999) Elevated serum TNF-alpha level as a link between endothelial dysfunction and insulin resistance in normotensive obese patients. Diabet Med 16:207–211 Winkler G, Lakatos P, Salamon F et al. (1999) Elevated serum TNF-alpha level as a link between endothelial dysfunction and insulin resistance in normotensive obese patients. Diabet Med 16:207–211
18.
Zurück zum Zitat Zinman B, Hanley AJ, Harris SB, Kwan J, Fantus IG (1999) Circulating tumor necrosis factor-alpha concentrations in a native Canadian population with high rates of type 2 diabetes mellitus. J Clin Endocrinol Metab 84:272–278PubMed Zinman B, Hanley AJ, Harris SB, Kwan J, Fantus IG (1999) Circulating tumor necrosis factor-alpha concentrations in a native Canadian population with high rates of type 2 diabetes mellitus. J Clin Endocrinol Metab 84:272–278PubMed
19.
Zurück zum Zitat Pfeiffer A, Janott J, Mohlig M et al. (1997) Circulating tumor necrosis factor alpha is elevated in male but not in female patients with type II diabetes mellitus. Horm Metab Res 29:111–114PubMed Pfeiffer A, Janott J, Mohlig M et al. (1997) Circulating tumor necrosis factor alpha is elevated in male but not in female patients with type II diabetes mellitus. Horm Metab Res 29:111–114PubMed
20.
Zurück zum Zitat Hotamisligil GS, Shargill NS, Spiegelman BM (1993) Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259:87–91PubMed Hotamisligil GS, Shargill NS, Spiegelman BM (1993) Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259:87–91PubMed
21.
Zurück zum Zitat Stephens JM, Pekala PH (1992) Transcriptional repression of the C/EBP-alpha and GLUT4 genes in 3T3-L1 adipocytes by tumor necrosis factor-alpha. Regulations is coordinate and independent of protein synthesis. J Biol Chem 267:13580–13584PubMed Stephens JM, Pekala PH (1992) Transcriptional repression of the C/EBP-alpha and GLUT4 genes in 3T3-L1 adipocytes by tumor necrosis factor-alpha. Regulations is coordinate and independent of protein synthesis. J Biol Chem 267:13580–13584PubMed
22.
Zurück zum Zitat Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM (1994) Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc Natl Acad Sci USA 91:4854–4858PubMed Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM (1994) Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc Natl Acad Sci USA 91:4854–4858PubMed
23.
Zurück zum Zitat Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM (1996) IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 271:665–668PubMed Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM (1996) IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 271:665–668PubMed
24.
Zurück zum Zitat Stephens JM, Lee J, Pilch PF (1997) Tumor necrosis factor-alpha-induced insulin resistance in 3T3-L1 adipocytes is accompanied by a loss of insulin receptor substrate-1 and GLUT4 expression without a loss of insulin receptor-mediated signal transduction. J Biol Chem 272:971–976CrossRefPubMed Stephens JM, Lee J, Pilch PF (1997) Tumor necrosis factor-alpha-induced insulin resistance in 3T3-L1 adipocytes is accompanied by a loss of insulin receptor substrate-1 and GLUT4 expression without a loss of insulin receptor-mediated signal transduction. J Biol Chem 272:971–976CrossRefPubMed
25.
Zurück zum Zitat Nolte LA, Hansen PA, Chen MM, Schluter JM, Gulve EA, Holloszy JO (1998) Short-term exposure to tumor necrosis factor-alpha does not affect insulin-stimulated glucose uptake in skeletal muscle. Diabetes 47:721–726PubMed Nolte LA, Hansen PA, Chen MM, Schluter JM, Gulve EA, Holloszy JO (1998) Short-term exposure to tumor necrosis factor-alpha does not affect insulin-stimulated glucose uptake in skeletal muscle. Diabetes 47:721–726PubMed
26.
Zurück zum Zitat Ofei F, Hurel S, Newkirk J, Sopwith M, Taylor R (1996) Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 45:881–885 Ofei F, Hurel S, Newkirk J, Sopwith M, Taylor R (1996) Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 45:881–885
27.
Zurück zum Zitat DeFronzo RA, Tobin JD, Andres R (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol Endocrinol Metab 237:E214–E223 DeFronzo RA, Tobin JD, Andres R (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol Endocrinol Metab 237:E214–E223
28.
Zurück zum Zitat Febbraio MA, Steensberg A, Fischer CP, Keller C, Hiscock N, Pedersen BK (2002) IL-6 activates HSP72 gene expression in human skeletal muscle. Biochem Biophys Res Commun 296:1264–1266CrossRefPubMed Febbraio MA, Steensberg A, Fischer CP, Keller C, Hiscock N, Pedersen BK (2002) IL-6 activates HSP72 gene expression in human skeletal muscle. Biochem Biophys Res Commun 296:1264–1266CrossRefPubMed
29.
Zurück zum Zitat Steensberg A, Keller C, Starkie RL, Osada T, Febbraio MA, Pedersen BK (2002) IL-6 and TNF-alpha expression in, and release from, contracting human skeletal muscle. Am J Physiol Endocrinol Metab 283:E1272–E1278PubMed Steensberg A, Keller C, Starkie RL, Osada T, Febbraio MA, Pedersen BK (2002) IL-6 and TNF-alpha expression in, and release from, contracting human skeletal muscle. Am J Physiol Endocrinol Metab 283:E1272–E1278PubMed
30.
Zurück zum Zitat Vozarova B, Weyer C, Hanson K, Tataranni PA, Bogardus C, Pratley RE (2001) Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes Res 9:414–417PubMed Vozarova B, Weyer C, Hanson K, Tataranni PA, Bogardus C, Pratley RE (2001) Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes Res 9:414–417PubMed
31.
Zurück zum Zitat Senn JJ, Klover PJ, Nowak IA, Mooney RA (2002) Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 51:3391–3399 Senn JJ, Klover PJ, Nowak IA, Mooney RA (2002) Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 51:3391–3399
32.
Zurück zum Zitat Stouthard JM, Romijn JA, van der Poll T et al. (1995) Endocrinologic and metabolic effects of interleukin-6 in humans. Am J Physiol Endocrinol Metab 268:E813–E819 Stouthard JM, Romijn JA, van der Poll T et al. (1995) Endocrinologic and metabolic effects of interleukin-6 in humans. Am J Physiol Endocrinol Metab 268:E813–E819
33.
Zurück zum Zitat Birkenkamp KU, Esselink MT, Kruijer W, Vellenga E (2000) An inhibitor of PI3-K differentially affects proliferation and IL-6 protein secretion in normal and leukemic myeloid cells depending on the stage of differentiation. Exp Hematol 28:1239–1249CrossRefPubMed Birkenkamp KU, Esselink MT, Kruijer W, Vellenga E (2000) An inhibitor of PI3-K differentially affects proliferation and IL-6 protein secretion in normal and leukemic myeloid cells depending on the stage of differentiation. Exp Hematol 28:1239–1249CrossRefPubMed
34.
Zurück zum Zitat Krogh-Madsen R, Plomgaard P, Keller P, Keller C, Pedersen BK (2004) Insulin stimulates interleukin-6 and tumor necrosis factor-{alpha} gene expression in human subcutaneous adipose tissue. Am J Physiol Endocrinol Metab 286:E234–E238CrossRefPubMed Krogh-Madsen R, Plomgaard P, Keller P, Keller C, Pedersen BK (2004) Insulin stimulates interleukin-6 and tumor necrosis factor-{alpha} gene expression in human subcutaneous adipose tissue. Am J Physiol Endocrinol Metab 286:E234–E238CrossRefPubMed
35.
Zurück zum Zitat Febbraio MA, Keenan J, Angus DJ, Campbell SE, Garnham AP (2000) Preexercise carbohydrate ingestion, glucose kinetics, and muscle glycogen use: effect of the glycemic index. J Appl Physiol 89:1845–1851 Febbraio MA, Keenan J, Angus DJ, Campbell SE, Garnham AP (2000) Preexercise carbohydrate ingestion, glucose kinetics, and muscle glycogen use: effect of the glycemic index. J Appl Physiol 89:1845–1851
36.
Zurück zum Zitat Febbraio MA, Steensberg A, Starkie RL, McConell GK, Kingwell BA (2003) Contracting skeletal muscle releases IL-6, but not TNF-α, in healthy subjects and patients with type 2 diabetes. Metabolism 52:939–954CrossRefPubMed Febbraio MA, Steensberg A, Starkie RL, McConell GK, Kingwell BA (2003) Contracting skeletal muscle releases IL-6, but not TNF-α, in healthy subjects and patients with type 2 diabetes. Metabolism 52:939–954CrossRefPubMed
37.
Zurück zum Zitat Bluher M, Kratzsch J, Paschke R (2001) Plasma levels of tumor necrosis factor-alpha, angiotensin II, growth hormone, and IGF-I are not elevated in insulin-resistant obese individuals with impaired glucose tolerance. Diabetes Care 24:328–334PubMed Bluher M, Kratzsch J, Paschke R (2001) Plasma levels of tumor necrosis factor-alpha, angiotensin II, growth hormone, and IGF-I are not elevated in insulin-resistant obese individuals with impaired glucose tolerance. Diabetes Care 24:328–334PubMed
38.
Zurück zum Zitat Paolisso G, Rizzo MR, Mazziotti G et al. (1998) Advancing age and insulin resistance: role of plasma tumor necrosis factor-alpha. Am J Physiol Endocrinol Metab 275:E294–E299 Paolisso G, Rizzo MR, Mazziotti G et al. (1998) Advancing age and insulin resistance: role of plasma tumor necrosis factor-alpha. Am J Physiol Endocrinol Metab 275:E294–E299
39.
Zurück zum Zitat Winkler G, Salamon F, Salamon D, Speer G, Simon K, Cseh K (1998) Elevated serum tumour necrosis factor-alpha levels can contribute to the insulin resistance in Type II (non-insulin-dependent) diabetes and in obesity. Diabetologia 41:860–861 Winkler G, Salamon F, Salamon D, Speer G, Simon K, Cseh K (1998) Elevated serum tumour necrosis factor-alpha levels can contribute to the insulin resistance in Type II (non-insulin-dependent) diabetes and in obesity. Diabetologia 41:860–861
40.
Zurück zum Zitat Starkie R, Ostrowski SR, Jauffred S, Febbraio M, Pedersen BK (2003) Exercise and IL-6 infusion inhibit endotoxin-induced TNF-alpha production in humans. FASEB J 17:884–886PubMed Starkie R, Ostrowski SR, Jauffred S, Febbraio M, Pedersen BK (2003) Exercise and IL-6 infusion inhibit endotoxin-induced TNF-alpha production in humans. FASEB J 17:884–886PubMed
41.
Zurück zum Zitat Dietze D, Koenen M, Rohrig K, Horikoshi H, Hauner H, Eckel J (2002) Impairment of insulin signaling in human skeletal muscle cells by co-culture with human adipocytes. Diabetes 51:2369–2376 Dietze D, Koenen M, Rohrig K, Horikoshi H, Hauner H, Eckel J (2002) Impairment of insulin signaling in human skeletal muscle cells by co-culture with human adipocytes. Diabetes 51:2369–2376
42.
Zurück zum Zitat Miyazaki Y, Glass L, Triplitt C, Wajcberg E, Mandarino LJ, DeFronzo RA (2002) Abdominal fat distribution and peripheral and hepatic insulin resistance in type 2 diabetes mellitus. Am J Physiol Endocrinol Metab 283:E1135–E1143PubMed Miyazaki Y, Glass L, Triplitt C, Wajcberg E, Mandarino LJ, DeFronzo RA (2002) Abdominal fat distribution and peripheral and hepatic insulin resistance in type 2 diabetes mellitus. Am J Physiol Endocrinol Metab 283:E1135–E1143PubMed
43.
Zurück zum Zitat Hotamisligil GS (2000) Molecular mechanisms of insulin resistance and the role of the adipocyte. Int J Obes Relat Metab Disord [Suppl 4] 24:S23–S27 Hotamisligil GS (2000) Molecular mechanisms of insulin resistance and the role of the adipocyte. Int J Obes Relat Metab Disord [Suppl 4] 24:S23–S27
Metadaten
Titel
Interleukin-6 and tumor necrosis factor-α are not increased in patients with Type 2 diabetes: evidence that plasma interleukin-6 is related to fat mass and not insulin responsiveness
verfasst von
A. L. Carey
C. R. Bruce
M. Sacchetti
M. J. Anderson
D. B. Olsen
B. Saltin
J. A. Hawley
M. A. Febbraio
Publikationsdatum
01.06.2004
Verlag
Springer-Verlag
Erschienen in
Diabetologia / Ausgabe 6/2004
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-004-1403-x

Weitere Artikel der Ausgabe 6/2004

Diabetologia 6/2004 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.